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Guillain-Barre syndrome is the most common polyneuropathy causing major
disability and respiratory failure. Respiratory complications are the main cause
of death. Improved respiratory care and new treatment strategies such as
plasmaphoresis and immunoglobulin have been shown to improve outcome. We
studied the course and outcome of 37 patients with Guillain-Barr6 syndrome
who were admitted to arehabilitation andrespiratory carefacility overa 10-year
period. There were 21 males and 16 females with a mean age of 62 + 3 years.
Fourteen patients developed respiratory failure requiring endotracheal intuba-
tion and mechanical ventilation. The mean duration of mechanical ventilation
was 38 ± 10 days. All patients were successfully liberated from the ventilator.
However, 83 percent ofthe patients were moderately to severely disabled at the
time ofdischarge. Thirteen out of 37 (35 percent) developed long-term disabil-
ity. None of the patients died over the period of follow-up. These results indi-
cate that early recognition and treatment of respiratory complications in
Guillain-Barre syndrome could reduce the morbidity and mortality of this con-
dition.
INTRODUCTION
Guillain-Barre syndrome is apolyneuropathy characterized by an acute onset ofsym-
metrical motor weakness with diminished or absent reflexes often associated with senso-
ry and autonomic disturbances and a pathological picture ofacute inflammatory demyeli-
nation and less commonly axonal damage. It is the most common acute neuropathy in the
developed world [1] with an annual incidence that varies from 0.5 to 2.0 per 100,000
worldwide [2] and may be increasing in the urban population above the age of50 [3]. In
the United States, the estimated annual incidence is 3.0cases per 100,000 population, with
a marked increase in risk above age 40, and an estimated death rate of628 cases per year
for the epoch 1985-1990 [4]. Guillain-Barre syndrome is also the most common neuro-
muscular cause of respiratory failure requiring ventilatory support with respiratory com-
plications [5]. However, in recent series, cardiac arrhythmias are shown to be the leading
cause of death in Guillain-Barre syndrome [6]. The improved prognosis in recent years
has largely resulted from advances in respiratory intensive care. This study reviews the
respiratory outcome of 37 patients with Guillain-Barre syndrome treated at Gaylord
Hospital Pulmonary Rehabilitation Unit from 1985-1995, and emphasizes current meth-
ods of treatment, respiratory care and rehabilitation.
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METHODS
A retrospective study of all patients discharged from Gaylord Hospital with a diag-
nosis of Guillain-Barre syndrome from 1985-1995 was conducted. Thirty-seven patients
fulfilled the diagnostic criteria set forth by the National Institute of Neurological
Disorders and Stroke as recently confirmed and expanded by Asbury and Comblath [7].
Briefly, patients had to have progressive motor weakness of more than one limb and be
areflexic. The majority ofpatients had cerebrospinal fluid and electrodiagnostic findings,
supporting the clinical diagnosis.
RESULTS
There were 21 males (mean age 58 ± 5 years) and 16 females (mean age 68 ± 3
years). As shown in Table 1, the majority ofpatients had apreceding event orillness with-
in two months of the onset of the syndrome. A flu-like illness, recent vaccination, upper
respiratory tract infection and diarrhea were the most commonly reported prodromal
events, with 41 percent of patients not reporting an apparent preceding event. Time to
maximum weakness from the onset ofprodromal symptoms was 12 ± 2 days with arange
oftwo to 74 days. From the first signofmuscle weakness to maximum weakness was only
2.7 ± 0.5 days indicating a precipitous decline in muscle function. Forty-three percent of
patients also had sensory involvement in addition to motor weakness and varying levels of
areflexia (Table 2). Fourteen ofthe 37 patients required intubation and mechanical venti-
lation, with nine progressing to tracheostomy. The onset ofrespiratory failure was fairly
acute in these patients developing within 4 ± 1 days from the start of peripheral muscle
weakness. The mean duration of mechanical ventilation was 38 ± 10 days with a median
of 20 days. The longest duration ofmechanical ventilation was 120 days, but all patients
were successfully liberated from the ventilator and decannulated. The mostcommon com-
plications of mechanical ventilation were post-tracheostomy bronchitis, mucus plugging,
atelectasis and nosocomial pneumonia.
Upon discharge, 83 percent of the patients were moderately to severely disabled
(Hughes disability scale) but stable enough to receive care andrehabilitation athome, with
no patient needing ventilatory assistance (Figure 1). After one year, twenty-five percent of
patients were without any symptoms or disability with another 34 percent having only
minor symptoms or disability. Forty-three percent ofpatients with moderate to severe dis-
ability did not improve beyond liberation from mechanical ventilation.
DISCUSSION
Clinical course and complications
Guillain-Barre syndrome accounts for significant utilization ofhospital resources and
rehabilitation facilities. The economic burden for the United States is estimated at $2 to 3
billion annually [4]. The length ofhospital stay increased with age with a median of nine
days (range, 0-502 days) for persons aged 15 to 44, 11 days (range, 0-835 days) for per-
sons aged 45 to 64 and 12 days (range, 0-537 days) forpersons over65 [4].Approximately
40 percent of patients hospitalized with this disease will require rehabilitation at an aver-
age adjusted cost of $31,636 per patient (1993 dollars), and the disease accounts for new
long-term disability in at least 1000 persons per year in the United States [8]. The need for
mechanical ventilation most strongly predicts the length of stay for these patients [9].
While this disease usually causes ascending paralysis and subsequent respiratory failure,
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Table 1. Demographics and clinical presentation.
Age, years
Gender
Male
Female
Preceding event
None
Flu-like illness
Vaccination
Respiratory tract infection
Diarrhea
Urinary tract infection
Lymphoma
Surgery
From onset ofprodromal symptoms to
muscle weakness, days
From onset of muscle weakness
to maximum weakness, days
62 + 3 (19-86)
21 (57%)
16 (43%)
15 (41%)
10 (27%)
10 (27%)
7 (19%)
2 (5%)
1 (3%)
1 (3%)
1 (3%)
9.3 + 1.8 (1-60)
2.7 + 0.5 (1-14)
Table 2. Neurologic and respiratory involvement in Guillain-Barre patients.
System Involvement Frequency (%)
Sensory 43
Autonomic 14
Bulbar 35
Respiratory 38
Mechanical ventilation 38
uncommonly, pure respiratory or autonomic failure [6, 10, 11] or symptoms of upper air-
way obstruction [12] can be the presenting manifestation. Approximately 10 to 30 percent
of patients with Guillain-Barre syndrome will have respiratory complications [5] with an
estimated 14 to 25 percent requiring mechanical ventilation [10]. There are several causes
of respiratory failure [5], including inability to protect the upper airway due to bulbar
involvement [13], hypoventilation from denervation of diaphragm [14] and intercostal
muscles and complications such as atelectasis (42 percent) and pneumonia (25 to 40 per-
cent) [15]. It is diaphragmatic muscle weakness due to neural involvement that correlates
best with ventilatory failure [5]. The central ventilatory drive response to CO2 has been
reported to be decreased and contributing to gas exchange abnormality independent of
concomitant respiratory muscle weakness [16]. Interestingly, impairment ofjoint position
and vibration sensation of the extremities in those patients with sensory involvement has
been associated with a greater need for ventilatory support [17]. The reduction in vital
capacity or maximum inspiratory mouth pressure may be the early signs ofimpending res-
piratory failure. As the disease progresses, the lowered lung volumes and flow rates impair
the effectiveness of the cough and sigh mechanisms leading to mucus plugging, atelecta-
sis, reduced lung compliance and increased venous admixture. The resultant increased
work of breathing further results in hypercapnia, hypoxemia, increased respiratory rates
and ventilatory failure. A reduction of vital capacity to less than 10 ml/kg is commonly
associated with hypoxemia and hypercapnia, both of which tend to worsen during sleep
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Figure 1. Disability at discharge and after, initial and long-term outcomes: Hughes Disability
Scale. The horizontal bars denote mean + SEM. The Hughes disability scale: Grade 0 (healthy),
Grade 1 (minor symptoms), Grade 2 (mildly disabled), Grade 3 (moderately disabled), Grade 4
(severely disabled), Grade 5 (requiring ventilatory assistance), Grade 6 (dead).
and the supine posture. Thus, patients with Guillain-Barre syndrome should be observed
in the hospital for at least a few days, until the course ofthe disease plateaus. Initially, vital
capacity, maximum inspiratory mouth pressure and arterial oxygen saturation should be
followed every six hours or more frequently, along with monitoring ofventilation by arte-
rial blood gas measurements. Those patients with vital capacity that is rapidly declining or
is less than 20 ml/kg are appropriate candidates for observation in the intensive care unit.
Patients with vital capacity less than 10 ml/kg and maximum inspiratory mouth pressure
less than -25 cm H20 usually require tracheal intubation and mechanical ventilation.
However, in patients who have intact upper airway protective mechanisms and less pro-
found respiratory muscle weakness with mild hypercapnic ventilatory, failure may only
require non-invasive ventilation using mask positive pressure ventilation or negative pres-
sure ventilation [18]. Nevertheless, these patients should also be monitored closely with
measurements of vital capacity, maximum inspiratory pressure and arterial blood gases to
detect those requiring endotracheal intubation and mechanical ventilation.
While elevated arterial PCO2 is the commonest abnormality detected on the arterial
blood gases, along with decreased arterial P02, careful attention should be paid to the alve-
olar-arterial oxygen gradient, a widening ofwhich can be the earliest sign of a pulmonary
embolism from deep venous thrombosis, occurring in up to two percent of patients [15].
Other complications ofprolonged immobility include hypostatic pneumonia, frank sepsis
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often originating from the lungs, the urinary tract or decubitus ulceration [8]. Meticulous
and vigorous pulmonary toilet and chest physiotherapy while on the ventilator and after
tracheal decannulation should minimize complications such as pneumonia and atelectasis.
While the trachea can be intubated for up to three weeks, beyond this the incidence of
laryngeal and tracheal complications rise sharply. Early tracheostomy in thesepatients will
improve pulmonary toilet, facilitate communication and allow the patient to eat in the
absence ofbulbar involvement and swallowing dysfunction. In keeping with the protract-
ed course of Guillain-Barre syndrome, the duration of mechanical ventilation is usually
prolonged, between 8 to 12 weeks in some series and up to 120 days in our study. Longer
durations ofventilation are distinctly unusual [19]. Case reports exist ofpatients requiring
prolonged ventilation, even up to seven years [20-25]. A few patients are reported to have
been liberated from ventilatory support up to 18 months after the initial illness [20]. The
standard criteria for weaning from mechanical ventilation are also applicable to Guillain-
Barre syndrome patients, though the vital capacity and the maximuminspiratory and trans-
diaphragmatic pressures have been separately favored by different groups as predictors of
successful extubation [5, 26, 27]. In the series reporting the longest periods ofventilatory
support, no patient could be weaned until the vital capacity improved to greater than one
liter [20]. More importantly, trends in serial measurements of vital capacity, maximum
voluntary ventilation, minute ventilation and maximum inspiratory pressure can be help-
ful in determining when to extubate. Tracheal decannulation can be safely undertaken
when secretions are minimal andeffectively cleared and swallowing is demonstrably coor-
dinated.
Cardiac complications are frequent, especially arrhythmias and cardiac arrest in the
setting of dysautonomia, with numerous reports ofdeath from the use of succinylcholine
for endotracheal intubation [5]. Furthermore, spectral analysis of heart rate and blood
pressure variation in mechanically ventilated patients with Guillain-Barre syndrome has
revealed a pattern of prominent broad respiratory heart rate variation peaks and narrow
blood pressure variation peaks to predict sinus arrest [28].
Treatment
Plasmapheresis has been shown to reduce the duration ofparalysis as well as reduce
the duration of mechanical ventilation by 50 percent [29, 30], with the optimum number
of plasma exchanges being shown to vary from two to four based on the severity of the
disease [31]. More recently, intravenous immunoglobulin therapy has been shown to be
equally efficacious [32, 33], with a study comparing the addition of methylprednisolone
being under way [33]. Steroids alone are ofno benefit [34]. To be effective, all treatments
need to be started within two weeks of illness or relapse.
Prognosis
The impact of respiratory failure on the disease outcome is profound. In one study
[9], patients requiring ventilatory support had lower Functional Independence Measure
Rasch converted scores on presentation, gained less on these scores on discharge and had
more than three times the acute length of stay than patients not requiring such support.
There are anecdotal reports of impaired ventilatory capacity [35], or sleep apnea [20],
occurring remote from apparent recovery from Guillain-Barre syndrome. The relapses do
occur after a long asymptomatic interval, but they are uncommon [36]. Recovery is the
rule in 80 percent ofpatients [2], with mortality rates varying from 3 to 18 percent over-
all [6] and as high as 15 to 30 percent in patients requiring mechanical ventilation [6, 15,
21]. The largest multi-center prospective trial to date, enrolling 297 patients, revealed that
patients with preceding Campylobacter infection and those with the axonal degeneration
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had a shortertime to peak ofweakness, aprolonged peakphase, and a worse outcome with
a high likelihood ofresidual muscle weakness. Older patients also fared worse [37] .
SUMMARY
Guillain-Barre syndrome is the most common cause ofrespiratory failure and chron-
ic disability due to neuromuscular disorders. Development ofrespiratory failure correlates
directly with high morbidity and mortality as aresult ofthis neuropathy. Early recognition
and optimal respiratory care should minimize mortality from this neuropathy.
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